Idarubicin
Acute Myeloid Leukemia, Del(5q31-Q32)
Bruno C. MedeirosSmall moleculePhase 2Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Acute Myeloid Leukemia, Del(5q31-Q32) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Alice Mims | Phase 3 | BBB |
CYTARABINE Alice Mims | Phase 3 | BBB |
Cyclophosphamide Sumithira Vasu | Phase 3 | BBB |
Fludarabine Rutgers, The State University of New Jersey | Phase 3 | BBB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Idarubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →